{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:53:12Z","timestamp":1792144392998,"version":"4.4.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014034","name":"Foundation for Research in Rheumatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["11-3"],"award-info":[{"award-number":["11-3"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["11-1"],"award-info":[{"award-number":["11-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Do491\/10-2"],"award-info":[{"award-number":["Do491\/10-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["13-1"],"award-info":[{"award-number":["13-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003067","name":"Kidney Foundation of Ohio","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.coi.2025.102712","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:55:50Z","timestamp":1766451350000},"page":"102712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Mapping the B-cell axis in Sj\u00f6gren\u2019s disease: repertoire, microenvironment, and potential routes to precision treatment"],"prefix":"10.1016","volume":"98","author":[{"given":"Loukas","family":"Chatzis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris Anastasios","family":"Palamidas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102712_bib1","first-page":"2336","article-title":"Pathogenesis of Sj\u00f6gren's disease: one year in review 2024","volume":"42","author":"Baldini","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2025.102712_bib2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.62.2.168","article-title":"The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102712_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000292","article-title":"SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjogren's syndrome","volume":"2","author":"Rose","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2025.102712_sbref4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/art.42683","article-title":"Multimodal single-cell sequencing of B cells in primary Sj\u00f6gren's syndrome","volume":"76","author":"Arvidsson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102712_sbref5","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-024-03283-z","article-title":"B cell receptor repertoire analysis in primary Sjogren's syndrome salivary glands identifies repertoire features associated with clinical activity","volume":"26","author":"Chang","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coi.2025.102712_bib6","doi-asserted-by":"crossref","first-page":"E579","DOI":"10.1503\/cmaj.122037","article-title":"Sj\u00f6gren syndrome","volume":"186","author":"Mavragani","year":"2014","journal-title":"CMAJ"},{"key":"10.1016\/j.coi.2025.102712_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594096","article-title":"Primary Sj\u00f6gren's syndrome of early and late onset: distinct clinical phenotypes and lymphoma development","volume":"11","author":"Goules","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102712_bib8","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1093\/rheumatology\/keab939","article-title":"Clinical picture, outcome and predictive factors of lymphoma in primary Sj\u00f6gren's syndrome: results from a harmonized dataset (1981-2021)","volume":"61","author":"Chatzis","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102712_bib9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0049-0172(00)80016-5","article-title":"Clinical evolution, and morbidity and mortality of primary Sj\u00f6gren's syndrome","volume":"29","author":"Skopouli","year":"2000","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102712_bib10","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/art.1780390508","article-title":"Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sj\u00f6gren's syndrome","volume":"39","author":"Tzioufas","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102712_bib11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaut.2009.10.004","article-title":"Characteristics of the minor salivary gland infiltrates in Sj\u00f6gren's syndrome","volume":"34","author":"Christodoulou","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102712_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102648","article-title":"A biomarker for lymphoma development in Sjogren's syndrome: salivary gland focus score","volume":"121","author":"Chatzis","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102712_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105406","article-title":"Current and future treatment in primary Sjogren's syndrome \u2014 a still challenging development","volume":"89","author":"Ritter","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.coi.2025.102712_sbref14","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102578","article-title":"Can we cure Sjogren's disease? Unmet needs and raising questions in the era of Precision medicine","volume":"95","author":"Chatzis","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2025.102712_bib15","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41591-024-03009-3","article-title":"CD40 ligand antagonist dazodalibep in Sj\u00f6gren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial","volume":"30","author":"St Clair","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2025.102712_bib16","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(24)01211-X","article-title":"Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sj\u00f6gren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study","volume":"404","author":"Fisher","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102712_bib17","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/S2665-9913(24)00183-8","article-title":"Identification and evolution of predictors of Sj\u00f6gren's disease-associated mucosa-associated lymphoid tissue lymphoma development over time: a case-control study","volume":"6","author":"Goules","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2025.102712_bib18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/path.6039","article-title":"Lymphoma-associated mutations in autoreactive memory B cells of patients with Sj\u00f6gren's syndrome","volume":"259","author":"Bende","year":"2023","journal-title":"J Pathol"},{"key":"10.1016\/j.coi.2025.102712_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02136","article-title":"Identification and characterization of post-activated B cells in systemic autoimmune diseases","volume":"10","author":"Weissenberg","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102712_bib20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri844","article-title":"BAFF: a fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2025.102712_bib21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/annrheumdis-2012-202071","article-title":"Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial","volume":"72","author":"Pollard","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102712_sbref22","article-title":"The role of B cell-activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102712_bib23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41584-021-00605-2","article-title":"Epithelial-immune cell interplay in primary Sj\u00f6gren syndrome salivary gland pathogenesis","volume":"17","author":"Verstappen","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2025.102712_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004112","article-title":"Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sj\u00f6gren's disease","volume":"10","author":"Felten","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2025.102712_bib25","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1136\/annrheumdis-2019-216588","article-title":"Salivary gland epithelial cells from patients with Sj\u00f6gren's syndrome induce B-lymphocyte survival and activation","volume":"79","author":"Rivi\u00e8re","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102712_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren's syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.coi.2025.102712_sbref27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103243","article-title":"Elevated unphosphorylated STAT1 and IRF9 in T and B cells of primary sjogren's syndrome: novel biomarkers for disease activity and subsets","volume":"147","author":"Ritter","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102712_bib28","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/art.40589","article-title":"JAK-1 inhibition suppresses interferon-induced BAFF production in human salivary gland: potential therapeutic strategy for primary Sj\u00f6gren's syndrome","volume":"70","author":"Lee","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102712_sbref29","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/ard-2023-224842","article-title":"Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sj\u00f6gren's disease","volume":"83","author":"Gupta","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102712_sbref30","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-63935-9","article-title":"Comparative single-cell and spatial profiling of anti-SSA-positive and anti-centromere-positive Sj\u00f6gren's disease reveals common and distinct immune activation and fibroblast-mediated inflammation","volume":"16","author":"Inamo","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102712_sbref31","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/s41423-025-01346-y","article-title":"The STING\/type I interferon axis drives the interplay between marginal zone B cells and T follicular helper cells in Sj\u00f6gren\u2019s disease","volume":"22","author":"Chen","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.coi.2025.102712_bib32","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1002\/art.11311","article-title":"Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sj\u00f6gren's syndrome","volume":"48","author":"Salomonsson","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102712_bib33","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1600-0714.2008.00674.x","article-title":"Follicular dendritic cells confirm lymphoid organization in the minor salivary glands of primary Sj\u00f6gren's syndrome","volume":"37","author":"Jonsson","year":"2008","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.coi.2025.102712_bib34","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.4049\/jimmunol.1201216","article-title":"Inducible tertiary lymphoid structures, autoimmunity, and exocrine dysfunction in a novel model of salivary gland inflammation in C57BL\/6 mice","volume":"189","author":"Bombardieri","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2025.102712_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107943","article-title":"Single-cell transcriptome profiling reveals immune and stromal cell heterogeneity in primary Sj\u00f6gren's syndrome","volume":"26","author":"Xiang","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.coi.2025.102712_bib36","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/ard.2010.144782","article-title":"Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sj\u00f6gren's syndrome","volume":"70","author":"Theander","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102712_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25063259","article-title":"B-cell activation biomarkers in salivary glands are related to lymphomagenesis in primary Sj\u00f6gren's disease: a pilot monocentric exploratory study","volume":"25","author":"Bruno","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2025.102712_bib38","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.4049\/jimmunol.180.7.5130","article-title":"CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization","volume":"180","author":"Barone","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2025.102712_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.705079","article-title":"Serum, but not saliva, CXCL13 levels associate with infiltrating CXCL13+ cells in the minor salivary gland lesions and other histologic parameters in patients with Sj\u00f6gren's syndrome","volume":"12","author":"Chatzis","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102712_bib40","doi-asserted-by":"crossref","DOI":"10.1186\/ar3504","article-title":"Impact of interleukin-21 in the pathogenesis of primary Sj\u00f6gren's syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands","volume":"13","author":"Kang","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coi.2025.102712_sbref41","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102539","article-title":"T cell-B cell interactions in human autoimmune diseases","volume":"93","author":"Sowerby","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2025.102712_bib42","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/art.20276","article-title":"Abnormalities in peripheral B cell memory of patients with primary Sjogren's syndrome","volume":"50","author":"Hansen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102712_bib43","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.jds.2023.12.024","article-title":"Profiles of peripheral B cell subsets in a cohort of primary Sj\u00f6gren's syndrome patients and their potential clinical significance","volume":"19","author":"Xing","year":"2024","journal-title":"J Dent Sci"},{"key":"10.1016\/j.coi.2025.102712_sbref44","article-title":"Decreased IgD- CD27- double negative B cells in Sj\u00f6gren\u2019s disease correlated with disease activity index","volume":"15","author":"Zhao","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2025.102712_bib45","article-title":"Interferon-\u03b1\u2013driven stratification of B cells reveals metabolic reprogramming of double-negative, naive and transitional cell subsets and refines molecular classification in Sj\u00f6gren\u2019s disease","author":"Iperi","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.coi.2025.102712_bib46","unstructured":"Chatzis L, Hemon P, Scuiller Y, Goules AV, Cornec D, Tzioufas AG, Pers JO: Deep spatial profiling unveils dominant double negative B cells in severe forms of Sj\u00f6gren\u2019s syndrome [abstract]. Edited by\u00a0American College of Rheumatology; 2024."},{"key":"10.1016\/j.coi.2025.102712_bib47","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","article-title":"Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus","volume":"49","author":"Jenks","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2025.102712_bib48","article-title":"IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c(hi)T-bet(+) B cells in SLE","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102712_bib49","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/art.42157","article-title":"Plasmablast-like phenotype among antigen-experienced CXCR5-CD19(low) B cells in systemic lupus erythematosus","volume":"74","author":"Szelinski","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102712_bib50","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41577-025-01141-w","article-title":"Defining immune reset: achieving sustained remission in autoimmune diseases","volume":"25","author":"Junt","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2025.102712_bib51","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1146\/annurev-immunol-092419-031130","article-title":"Age-associated B cells","volume":"38","author":"Cancro","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.coi.2025.102712_sbref51","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1007\/s11357-024-01159-3","article-title":"Age-associated B cell infiltration in salivary glands represents a hallmark of Sj\u00f6gren's-like disease in aging mice","volume":"46","author":"Bagavant","year":"2024","journal-title":"Geroscience"},{"key":"10.1016\/j.coi.2025.102712_sbref52","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jleuko\/qiad135","article-title":"TLR7 activation of age-associated B cells mediates disease in a mouse model of primary Sj\u00f6gren's disease","volume":"115","author":"Punnanitinont","year":"2024","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.coi.2025.102712_bib54","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41584-024-01179-5","article-title":"The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus","volume":"20","author":"Dorner","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2025.102712_bib55","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/s41423-019-0227-z","article-title":"IL-10-producing regulatory B cells restrain the T follicular helper cell response in primary Sj\u00f6gren's syndrome","volume":"16","author":"Lin","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.coi.2025.102712_bib56","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1136\/annrheumdis-2024-eular.5766","article-title":"AB0801 glycolysis expression in lymphocytes infiltrating Sjogren\u2019s disease salivary glands. A preliminary analysis on the expression of the glucose transporter GLUT-1","volume":"83","author":"Simoncelli","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102712_bib57","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/imm.13580","article-title":"mTORC1-GLUT1-mediated glucose metabolism drives hyperactivation of B cells in primary Sjogren's syndrome","volume":"168","author":"Luo","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.coi.2025.102712_bib58","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41584-025-01267-0","article-title":"Immunometabolism in systemic lupus erythematosus","volume":"21","author":"Pati\u00f1o-Martinez","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2025.102712_bib59","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/art.42433","article-title":"Amelioration of autoimmunity in a lupus mouse model by modulation of T-bet-promoted energy metabolism in pathogenic age\/autoimmune-associated B cells","volume":"75","author":"Han","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102712_bib60","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2017.03.012","article-title":"FcRL4(+) B-cells in salivary glands of primary Sj\u00f6gren's syndrome patients","volume":"81","author":"Haacke","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102712_bib61","first-page":"42","article-title":"Presence of intraepithelial B-lymphocytes is associated with the formation of lymphoepithelial lesions in salivary glands of primary Sj\u00f6gren's syndrome patients","volume":"37","author":"van Ginkel","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2025.102712_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102439","article-title":"Gene expression profiling of epithelium-associated FcRL4(+) B cells in primary Sj\u00f6gren's syndrome reveals a pathogenic signature","volume":"109","author":"Verstappen","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102712_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01486","article-title":"Repertoire analysis of B-cells located in striated ducts of salivary glands of patients with Sj\u00f6gren's syndrome","volume":"11","author":"Visser","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102712_bib64","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1136\/annrheumdis-2013-204116","article-title":"Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis","volume":"74","author":"Yeo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102712_bib65","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/art.42550","article-title":"Association between Bruton's tyrosine kinase gene overexpression and risk of lymphoma in primary Sj\u00f6gren's syndrome","volume":"75","author":"Duret","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102712_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24098385","article-title":"B-cell receptor signaling is thought to be a bridge between primary Sjogren syndrome and diffuse large B-cell lymphoma","volume":"24","author":"Mohammadnezhad","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2025.102712_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1130686","article-title":"Extranodal marginal zone lymphoma clonotypes are detectable prior to eMZL diagnosis in tissue biopsies and peripheral blood of Sj\u00f6gren's syndrome patients through immunogenetics","volume":"13","author":"Kolijn","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.coi.2025.102712_sbref67","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41584-024-01135-3","article-title":"Update on the pathophysiology and treatment of primary Sj\u00f6gren syndrome","volume":"20","author":"Baldini","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2025.102712_bib69","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren's syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102712_bib70","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102712_bib71","article-title":"Evaluation of the dual mode of action of Ianalumab (VAY736) in the circulation and salivary gland tissue of patients with Sj\u00f6gren\u2019s disease: results from a phase 2 mechanistic study","volume":"77","author":"Cornec","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102712_bib72","article-title":"Efficacy and safety of telitacicept in patients with Sj\u00f6gren\u2019s disease: results from a multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical study","volume":"77","author":"Xu","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102712_bib73","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard-2023-224691","article-title":"Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sj\u00f6gren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial","volume":"83","author":"D\u00f6rner","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102712_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2024-eular.LBA90","article-title":"LBA0010 efficacy and safety of nipocalimab, an anti-FcRn monoclonal antibody, in primary Sjogren\u2019s disease: results from a phase 2, multicenter, randomized, placebo-controlled, double-blind study (DAHLIAS)","volume":"83","author":"Gottenberg","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102712_bib75","article-title":"OP0041 treatment of primary Sj\u00f6gren's disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod","volume":"84","author":"Peene","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102712_bib76","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/art.42612","article-title":"Expert perspective: challenges in Sj\u00f6gren's disease","volume":"75","author":"Nocturne","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102712_bib77","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/1744666X.2023.2234641","article-title":"Why do drug treatments fail in Sj\u00f6gren's disease? Considerations for treatment, trial design and interpretation of clinical efficacy","volume":"19","author":"Arends","year":"2023","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:03:04Z","timestamp":1780635784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525001888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":77,"alternative-id":["S0952791525001888"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102712","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mapping the B-cell axis in Sj\u00f6gren\u2019s disease: repertoire, microenvironment, and potential routes to precision treatment","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102712"}}